SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

 6 ETF Predictions for 2026

2026 could favor SPY, SLV, KBWB, TAN & global ETFs as AI, metals, banks and clean energy shape the next leg of market gains.

Best-Performing Sector ETFs of 2025

Metals, shipping and rare earth ETFs like SLVP, BWET and SETM led 2025, and SPY has gained 14.8% YTD despite AI, tariff and rate jitters.

<ul class="summary-bullets"><li>XPeng’s diversified EV lineup spans premium SUVs, sedans, MPVs, and budget models.</li><li>This allowed the company to respond quickly to shifting demand while leveraging AI-driven software, in-house chips, and advanced driver-assistance systems.</li><li>Improving gross margins and early investments in robotics and AI technologies have strengthened its long-term growth narrative.</li></ul>Tesla, Inc. (TSLA) stock had a sputtering start to the year but came back from behind to trade with handsome gains as the year draws to a close. If Tesla’s second-half pick-up has left you in awe, wait till you hear about this smaller player, whose market capitalization is roughly one-ninth that of the U.S. electric-vehicle (EV) giant.Guangzhou, Guangdong-based XPeng, Inc. (XPEV) has seen its shares surge by about 56% versus Tesla’s 14% gain. Its outperformance is driven by its nimbleness in adapting to changing EV market dynamics, its use of artificial intelligence-enabled vehicle technology, and its foray into robotics.<img src="https://news.stocktwits-cdn.com/XPEV_vs_TSLA_YTD_Return_png_3a33086c4d.webp" alt="XPEV vs TSLA YTD Return.png">Source: Koyfin<h2 class="st-heading-2">XPeng’s Lineup</h2>Founded in 2014, XPeng took four years to launch its first model, the G3 SUV, and the company began deliveries of its second model, the P4 four-door sedan, in 2020. The company’s current vehicle lineup includes the following models:<figure class="table" style="width:100%;"><table class="ck-table-resized"><colgroup><col style="width:8.75%;"><col style="width:26.58%;"><col style="width:12.33%;"><col style="width:12.65%;"><col style="width:28.98%;"><col style="width:10.71%;"></colgroup><tbody><tr><td>&nbsp;</td><td>Vehicle Type</td><td>Range (CLTC)</td><td>0-100 km acceleration</td><td>Other features</td><td>Starting Price</td></tr><tr><td>X9</td><td>Ultra smart 7-seater (multi-purpose vehicle)</td><td>upto 702 Km</td><td>5.7s</td><td>-XOS Tinaji In-car OS -XNG full-scenario ADAS -Qualcomm Snapdragon SA8295P chip</td><td>350,000 yuan</td></tr><tr><td>G9</td><td>Premium SUV</td><td>Upto 585 Km</td><td>4.2s</td><td>-full-scene AI voice control -XPilot Assist advanced tech</td><td>248,800 yuan</td></tr><tr><td>G6</td><td>Coupe SUV</td><td>Upto 427 Km</td><td>4.13s</td><td>-XPeng full-stack Lofic architecture -XPilot Assist advanced tech -Sensor suite</td><td>176,800 yuan</td></tr><tr><td>P7 (new)</td><td>Sports sedan</td><td>Upto 576 Km</td><td>4.1s</td><td>-XPilot Assist -in-house Turing AI chips</td><td>219,800 yuan</td></tr></tbody></table></figure>Source: XPengXPeng also has a lineup of budget EVs marketed under the Mona subbrand. It launched the Mona M03, a hatchback coupe, in August 2024. It has a starting price of under 120,000 yuan and is pitched against Tesla’s Model 3 in China.&nbsp;<h2 class="st-heading-2">XPeng’s Deliveries Momentum Accelerates</h2>Quarterly deliveries are at a record, with sales showing sequential revenue growth since the first quarter of 2024. The third-quarter results released in mid-November showed a nearly 150% year-over-year (YoY) increase in deliveries to 116,007 units. The company rolled out its one millionth EV from its factory in November.<img src="https://news.stocktwits-cdn.com/Tesla_Quarterly_deliveries_png_75680a00ab.webp" alt="Tesla Quarterly deliveries.png">Source: The FlyThe revenue growth has kept pace with the rise in deliveries, with the latest quarterly number doubling from a year ago and rising 11.5% from the previous quarter.<img src="https://news.stocktwits-cdn.com/X_Peng_Revenue_Rises_In_Tandem_With_Deliveries_png_8b10b10367.webp" alt="XPeng_Revenue_Rises_In_Tandem_With_Deliveries.png">Source: Fiscal.aiGross margin has been on an upward trajectory since it inflected higher in the fourth quarter of 2023. Tesla, meanwhile, has traced a downtrend, stung by slowing deliveries and revenue growth and the absence of the high-margin regulatory EV credit.<img src="https://news.stocktwits-cdn.com/XPEV_Vs_TSLA_Margin_Profile_png_b8bce78307.webp" alt="XPEV_Vs_TSLA_Margin_Profile.png">Source:&nbsp;Fiscal.ai<h2 class="st-heading-2">XPeng’s Robotics Opportunity</h2>The Chinese EV maker, which prides itself on being a tech innovator, showcased its “IRON” robot earlier this year. The robot, which has a lifelike exterior and posture, will likely be mass-produced by the end of 2026 and introduced in factories and sales channels.<figure class="image"><img style="aspect-ratio:653/644;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_8_37_54_AM_png_4b6c445dbf.webp" alt="Screenshot 2025-12-18 at 8.37.54 AM.png" width="653" height="644"></figure>&nbsp;<h2 class="st-heading-2">But Retail Holds Back</h2>Sentiment among Stocktwits users toward XPEV was ‘bearish’ at the last reading, and it has remained depressed for much of this year.&nbsp;<figure class="image"><img style="aspect-ratio:715/441;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_8_42_26_AM_png_98da42b04b.webp" alt="Screenshot 2025-12-18 at 8.42.26 AM.png" width="715" height="441"></figure>&nbsp;&nbsp;Wall Street analysts, however, are optimistic. Nearly 80% of the 29 analysts covering the stock have ‘Buy’ or ‘Strong Buy’ ratings. The average analyst price target for the stock is $28.38, implying a 57% upside from the last close.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/obscure-indian-chip-stock-outruns-nvidia-in-6000-percent-ai-rally-this-year/cLegN4oREAL">Forget Nvidia — This Obscure Indian Chip Stock Just Became the World’s Best-Performing AI Play With 6,000% YTD Surge</a>

The Xpeng P7 is on display during the 2025 Guangzhou International Automobile Exhibition at China Import and Export Fair Complex on December 2, 2025.

Tesla Stock Had The EV Spotlight This Year — This Chinese Rival Took The Trophy

 XPeng has outperformed Tesla in 2025, driven by strong delivery growth, expanding EV lineup, and improving margins.

Equity

 XPeng has outperformed Tesla in 2025, driven by strong delivery growth, expanding EV lineup, and improving margins.



Will Clean Energy ETFs Lose Momentum on Russia's REE Move?

Putin's rare earth extraction push may spark supply concerns, but clean energy ETFs like ICLN should stay resilient amid global green momentum. 

The Zacks Analyst Blog Highlights ICLN, QCLN, ACES and PBW

A new U.S.-China rare earth deal could recharge clean energy ETFs like ICLN, QCLN, ACES, and PBW by easing supply-chain strains and stabilizing input costs.

U.S.-China Signs 1-Year Rare Earth Deal: Will Clean Energy ETFs Gain?

A new U.S.-China rare earth deal lifts hopes for clean energy ETFs, like ICLN and PBW, as supply chains stabilize and investor optimism returns.  

As Renewables Eclipse Coal, Is it Time to Invest in Clean Energy ETFs?

Renewables have overtaken coal in global power generation, putting clean energy ETFs like ICLN, QCLN and PBW in sharp investor focus.


Are Green ETFs in the Crosshairs? Navigating the Rare Earth Supply Shock

China's rare earth export curbs threaten the clean energy supply chain, but global exposure helps ETFs like PBW, FRNW, and ICLN stay resilient.  

Renewable Energy ETFs on Pace to See Best Year Since 2020: Here's Why

Clean energy rallies on several factors, with PBW ETF up 7% on Oct. 13, surging 126% in six months as AI demand & policy clarity boost renewables.

Shining a Light on 5 Clean Energy ETFs as We Step Into Q4 

Clean energy ETFs -ICLN, QCLN, PBW, ACES and FRNW - surge as global investment hits records, with momentum set to test U.S. policy headwinds in Q4.   

PBW
Invesco WilderHill Clean Energy ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PBW News

PBWInvesco WilderHill Clean Energy ETF